NasdaqGM - Nasdaq Real Time Price USD

Verona Pharma plc (VRNA)

Compare
29.99 +0.59 (+2.01%)
At close: September 20 at 4:00 PM EDT
29.99 0.00 (0.00%)
After hours: September 20 at 5:39 PM EDT
Loading Chart for VRNA
DELL
  • Previous Close 29.40
  • Open 29.47
  • Bid 29.97 x 100
  • Ask 30.03 x 200
  • Day's Range 29.39 - 30.30
  • 52 Week Range 11.39 - 30.73
  • Volume 545,526
  • Avg. Volume 1,451,247
  • Market Cap (intraday) 2.436B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) --
  • EPS (TTM) -1.60
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 35.79

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

www.veronapharma.com

79

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VRNA

View More

Performance Overview: VRNA

Trailing total returns as of 9/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VRNA
50.86%
MSCI WORLD
16.02%

1-Year Return

VRNA
77.04%
MSCI WORLD
25.22%

3-Year Return

VRNA
440.36%
MSCI WORLD
20.70%

5-Year Return

VRNA
535.38%
MSCI WORLD
67.31%

Compare To: VRNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VRNA

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    2.44B

  • Enterprise Value

    2.15B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    14.48

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.83%

  • Return on Equity (ttm)

    -56.85%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -125.45M

  • Diluted EPS (ttm)

    -1.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    404.6M

  • Total Debt/Equity (mrq)

    72.62%

  • Levered Free Cash Flow (ttm)

    -10.48M

Research Analysis: VRNA

View More

Company Insights: VRNA

Research Reports: VRNA

View More

People Also Watch